FDA grants priority review for Bayer regorafenib NDA
The submission was based upon data from the pivotal, global Phase III CORRECT study. Regorafenib is an investigational oral multi-kinase inhibitor and is currently being investigated in clinical
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).
The partnership will use IDRI’s synthetic adjuvants in conjunction with Soligenix’s proprietary subunit proteins and thermostability platform (known as ThermoVax). Soligenix president and chief executive officer Christopher Schaber